 TEL AVIV, Israel, Oct. 13, 2021 GLOBE NEWSWIRE -- InspireMD, Inc. Nasdaq: NSPR, a global developer of the CGuardTM Embolic Prevention Stent System EPS device for the treatment of Carotid Artery Disease CAD and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of Medical Devices and Health Technologies CNEDIMTS of the French National Authority for Health HAS regarding reimbursement in France, and the CGuard EPS is being added to the list of reimbursed medical products LPPR effective October 25, 2021. This was the final step to full commercial launch of CGuard EPS following CNEDIMTS positive opinion for reimbursement received by the Company on May 11, 2021 for the treatment of symptomatic and non-symptomatic lesions when surgery is not indicated. 